Whats the difference between omeprazole and pantoprazole

[Article in Spanish]

Affiliations

• PMID: 14708472

Clinical Trial

[Acid-supressing capacity of omeprazole 20 mg tablets vs pantoprazole 20 and 40 mg tablets. A pilot study in volunteers]

[Article in Spanish]

R Corti et al. Acta Gastroenterol Latinoam. 2003.

Abstract

Objective: To compare the acid-supressing capacity of omeprazole (OZ) 20 mg tablets vs pantoprazole (PZ) 20 and 40 mg tablets, in healthy volunteers, with 24-h intragastric pH-metry.

Material and methods: Open, randomized, cross-over trial in 10 healthy volunteers; on days 0.8 and 22, 24-h intragastric pH-metry. Day 0, basal, thereafter 7 days with OZ or PZ 20 mg/day; day 8, pH-metry, then "wash out" for 7 days and thereafter 7 more days' therapy with PZ or OZ. On day 22 a 24-h intragastric pH control was performed again. In the last treatment stage, all of them were administered pantoprazole 40 mg/day for 8 days again with a 24-h pH recording at the end.

Results: 24-h pH-metry expressed as the time (hours) in which the pH was < or = 4 and the values as mean +/- standard deviation. BASAL 22.12 +/- 1.54, POST-OZ 9.78 +/- 6.72, POST-PZ 20 15.65 +/- 5.65, POST-PZ 40 8.57 +/- 5.93. Statistical evaluation with two way repeated measures ANOVA p < 0.0001. Newman Keuls post-hoc test: (1) vs (2) p < 0.003; (1) vs (3) p < 0.03; (2) vs (4) 0.65.

Conclusions: According to the results it might be stated that both proton pump inhibitors have acid-supressing capacity and omeprazole in equal dosis is more effective than pantoprazole as acid-supressor, with statistically significative differences. There was no difference between 20 mg omeprazole and 40 mg pantoprazole.

Similar articles

• Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg.

  Florent C, Forestier S. Florent C, et al. Eur J Gastroenterol Hepatol. 1997 Feb;9(2):195-200. doi: 10.1097/00042737-199702000-00017. Eur J Gastroenterol Hepatol. 1997. PMID: 9058634 Clinical Trial.

• Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.

  Hartmann M, Theiss U, Huber R, Lühmann R, Bliesath H, Wurst W, Lücker PW. Hartmann M, et al. Aliment Pharmacol Ther. 1996 Jun;10(3):359-66. doi: 10.1111/j.0953-0673.1996.00359.x. Aliment Pharmacol Ther. 1996. PMID: 8791964 Clinical Trial.

• Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.

  Pratha VS, Hogan DL, Lane JR, Williams PJ, Burton MS, Lynn RB, Karlstadt RG. Pratha VS, et al. Dig Dis Sci. 2006 Jan;51(1):123-31. doi: 10.1007/s10620-006-3096-0. Dig Dis Sci. 2006. PMID: 16416224 Clinical Trial.

• Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans.

  Londong W. Londong W. Aliment Pharmacol Ther. 1994;8 Suppl 1:39-46. doi: 10.1111/j.1365-2036.1994.tb00239.x. Aliment Pharmacol Ther. 1994. PMID: 8180293 Review.

• Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.

  Andersson T. Andersson T. Clin Pharmacokinet. 1996 Jul;31(1):9-28. doi: 10.2165/00003088-199631010-00002. Clin Pharmacokinet. 1996. PMID: 8827397 Review.

Publication types

MeSH terms

Substances

Background: Pantoprazole is a new substituted benzimidazole which is a potent inhibitor of gastric acid secretion by its action upon H+,K(+)-ATPase.

Methods: The proton pump inhibitors pantoprazole and omeprazole were compared in a randomized, double-blind study in 219 patients with benign gastric ulcers. Patients received either pantoprazole 40 mg (n = 146) or omeprazole 20 mg (n = 73), once daily before breakfast for 4 weeks. Treatment was extended for a further 4 weeks if the ulcer had not healed.

Results: After 4 weeks, complete ulcer healing was seen in 88% of protocol-correct patients given pantoprazole and in 77% given omeprazole (between-group difference P < 0.05). At 8 weeks, the corresponding values were 97% and 96% (not significant). In the comparative intention-to-treat analysis there were no statistical differences between the treatment groups. Among the patients who had ulcer pain prior to treatment, 79% of the pantoprazole group and 68% of the omeprazole group were pain-free after 2 weeks, and after 4 weeks 88% and 81%, respectively (not significant). Pronounced improvement in the other gastrointestinal symptoms was seen in both groups. Only 10% of patients in each group reported adverse events. There were moderate increases in fasting serum gastrin levels with both treatments at 4 and 8 weeks.

Conclusion: Pantoprazole, 40 mg once daily in the morning, is a highly effective, well tolerated treatment for acute, benign gastric ulcer. Pantoprazole and omeprazole were equally safe in the therapy of gastric ulcer.